Drägerwerk AG & Co. KGaA

  • WKN: 555060
  • ISIN: DE0005550602
  • Land: Deutschland

Nachricht vom 14.07.2021 | 19:29

Drägerwerk AG & Co. KGaA: Business development in the first half year significantly above prior year despite lower earnings in the second quarter

Drägerwerk AG & Co. KGaA / Key word(s): Half Year Results
Drägerwerk AG & Co. KGaA: Business development in the first half year significantly above prior year despite lower earnings in the second quarter

14-Jul-2021 / 19:29 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Ad-hoc notification in accordance with Sec. 17 of the MAR

Drägerwerk AG & Co. KGaA: Business development in the first half year significantly above prior year despite lower earnings in the second quarter

Lübeck, July 14, 2021

In the first half of 2021, Dräger's net sales and earnings were significantly above the prior-year figures. Based on preliminary business figures, the Group's net sales increased currency-adjusted by 17.3 percent (nominal 14.3 percent) to around EUR 1,633 million (6 months 2020: EUR 1,428.4 million). At around EUR 209 million, EBIT generated in the first half of the year was significantly higher than in the previous year (6 months 2020: EUR 102 million).

At around EUR 738 million order entry in the second quarter was at a similarly high level as in the first three months of the year (Q1 2021: EUR 739.8 million) due to the continuing high demand in connection with the coronavirus pandemic. Net sales were around EUR 841 million, a currency-adjusted increase of 9.0 percent (nominal: 6.7 percent) compared to the prior year's period (Q2 2020: EUR 788.4 million). EBIT came out below the level of the previous year at around EUR 80 million (Q2 2020: EUR 102 million). This was due to the lower gross margin of around 46 percent (Q2 2020: 49.2 percent) and higher functional expenses.

Due to the better than expected order development, Dräger had already raised its guidance on June 21. Following the record year 2020, management expects the Dräger Group's net sales to decline currency-adjusted by between -2.0 and -6.0 percent (nominal: -3.0 to -7.0 percent) in the current fiscal year. The EBIT margin is expected to be between 8.0 and 11.0 percent. Dräger expects pandemic-related demand to normalize in the second half of the year and does not anticipate comparable demand in the coming year.

Dräger will publish its full results for the first six months of the fiscal year on July 29, 2021.

Drägerwerk AG & Co. KGaA
Moislinger Allee 53-55
23558 Lübeck, Deutschland

Investor Relations:
Thomas Fischler
Tel. +49 451 882-2685

Corporate Communications:
Melanie Kamann
Tel. +49 451 882-3998

This ad hoc report contains statements on the future development of Dräger Group. These forward-looking statements are based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to date. They were compiled to the best of the company's knowledge. Dräger does not provide any warranty nor assume any responsibility for the future developments and results described above. These are dependent on a number of factors. They entail various risks and contingencies outside of the company's influence and are based on assumptions which could prove to be incorrect. Dräger does not assume any responsibility for updating the forward-looking statements contained in this report. This does not infringe any legal stipulations on the adjustment of forecasts. Please go to Investor Relations / Definitions of financial indicators at www.draeger.com for information on alternative performance measures used.

14-Jul-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Symrise verlängert Vorstandsvertrag von Dr. Heinz-Jürgen Bertram vorzeitig bis 2025

01. Dezember 2021, 15:38

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index

01. Dezember 2021